Form
SCHEDULE 13D/A
Active or control-oriented beneficial ownership filing.
Cambridge Equities, LP - 23 Feb 2026 SCHEDULE 13D/A Report for ImmunityBio, Inc. Common Stock, par value $0.0001 per share (IBRX)
- Filing manager
- Cambridge Equities, LP
- Reporting owner
- Patrick Soon-Shiong
- Beneficially owned shares
- 745,576,456 shares
- Large-stake signal
-
Ownership
66%Beneficial ownership of this reported class.
Shares
745,576,456 sharesShares beneficially owned as disclosed.
Event date
23 Feb 2026Date tied to the ownership event or amendment.
Accepted by SEC
25 Feb 2026EDGAR acceptance date.
How to read this large-stake filing
- Schedule 13D/G filings focus on beneficial ownership stakes, not a full portfolio.
- Compare this filing with the holder history and issuer page before treating the percentage as a current position.
- Use amendments to understand whether the disclosed stake increased, decreased, or changed reporting status.
- Class ownership
- 66%
- Symbol
- IBRX
- Shares outstanding
- 1,124,549,707 shares
- SEC form
- SCHEDULE 13D/A
- Accepted by SEC
- 25 Feb 2026, 21:51:53 UTC
- Event date
- 23 Feb 2026
- Prior SEC filing
- 10 Nov 2025
- Source filing
- View source filing
Ownership signal
CIK-linked ownership evidence from parsed SEC filings.
2 signals
Subject security
Names, identifiers, and filing context for this profile.
2 source fields
Source evidence
Original filing metadata and source links for verification.
5 source fields
Key filing fact
Cambridge Equities, LP disclosed 66% ownership in ImmunityBio, Inc. Common Stock, par value $0.0001 per share (IBRX) on 23 Feb 2026.
Key facts
- Cambridge Equities, LP filed SCHEDULE 13D/A for ImmunityBio, Inc. Common Stock, par value $0.0001 per share (IBRX).
- Disclosed ownership: 66%.
- Date of event: 23 Feb 2026.
Change
- Previous schedule filing date: 10 Nov 2025.
- Current filing was accepted on 25 Feb 2026, 21:51.
Research use
- This page turns one Schedule 13D/G filing into a quick large-stake read before the raw reporting-person rows.
- Use the linked SEC filing as the source of truth for ownership percentages, shares, and reporting-party details.
Evidence
Backed by Schedule 13D/13G
View source filing
Beneficial ownership values are sourced from the original SEC Schedule 13D/13G filing.
Reporting persons
Disclosed reporting parties (6)
Names, ownership percentages, voting power, signatures, titles, and CIKs as disclosed in this Schedule 13D/G filing.
| Name | Ownership | Shares owned | Sole voting power | Shared voting power | Signature | Title | CIK |
|---|---|---|---|---|---|---|---|
| Cambridge Equities, LP | 26% | 261,705,814 | 0 | 261,705,814 | /s/ Charles Kenworthy | Charles Kenworthy, Manager of MP 13 Ventures, LLC, the General Partner of Cambridge Equities, LP | 0001629222 |
| MP 13 Ventures, LLC | 26% | 261,705,814 | 0 | 261,705,814 | /s/ Charles Kenworthy | Charles Kenworthy, Manager | 0001629186 |
| NantWorks, LLC | 9.6% | 98,535,253 | 0 | 98,535,253 | /s/ Robert Morse | Robert Morse, CFO of NantWorks, LLC | 0001675760 |
| Nant Capital, LLC | 30% | 339,465,529 | 0 | 339,465,529 | /s/ Charles Kenworthy | Charles Kenworthy, Manager of Nant Capital, LLC | 0001675758 |
| California Capital Equity, LLC | 10% | 106,511,412 | 0 | 106,511,412 | /s/ Charles Kenworthy | Charles Kenworthy, Manager of California Capital Equity, LLC | 0001517764 |
| Patrick Soon-Shiong | 66% | 745,576,456 | 32,275,375 | 713,301,081 | /s/ Patrick Soon-Shiong | Patrick Soon-Shiong | 0001189020 |
CIK / CUSIP context first